It’s hard to say the precise moment when CBD, the voguish cannabis derivative, went from being a fidget spinner alternative for stoners to a mainstream panacea.
Maybe it was in January, when Mandy Moore, hours before the Golden Globes, told Coveteur that she was experimenting with CBD oil to relieve the pain from wearing high heels. “It could be a really exciting evening,” she said. “I could be floating this year.”
Maybe it was in July, when Willie Nelson introduced a line of CBD-infused coffee beans called Willie’s Remedy. “It’s two of my favorites, together in the perfect combination,” he said in a statement.
Or maybe it was earlier this month, when Dr. Sanjay Gupta gave a qualified endorsement of CBD on “The Dr. Oz Show.” “I think there is a legitimate medicine here,” he said. “We’re talking about something that could really help people.”
So the question now becomes: Is this the dawning of a new miracle elixir, or does all the hype mean we have already reached Peak CBD?
Either way, it would be hard to script a more of-the-moment salve for a nation on edge. With its proponents claiming that CBD treats ailments as diverse as inflammation, pain, acne, anxiety, insomnia, depression, post-traumatic stress and even cancer, it’s easy to wonder if this all natural, non-psychotropic and widely available cousin of marijuana represents a cure for the 21st century itself.
The ice caps are melting, the Dow teeters, and a divided country seems headed for divorce court. Is it any wonder, then, that everyone seems to be reaching for the tincture?
“Right now, CBD is the chemical equivalent to Bitcoin in 2016,” said Jason DeLand, a New York advertising executive and a board member of Dosist, a cannabis company in Santa Monica, Calif., that makes disposable vape pens with CBD. “It’s hot, everywhere and yet almost nobody understands it.”
If you ask most people what is the most important factor when considering purchasing one hemp variety (cultivar) over another, nine out of 10 people will say CBD%. But that is only a part of the story.
Because of its early acceptance as a beneficial compound, most hemp consumers are very familiar with the various benefits of CBD. But as we learn more about hemp and the research is beginning to document, there are many additional compounds in addition to CBD that contribute to its beneficial attributes.
At this time there are almost 500 different compounds in hemp which have been identified which may prove to have beneficial qualities, not to mention the interaction of these compounds in what is commonly referred to as the “Entourage effect” where the sum of these different elements is greater than the individual parts.
We are now starting to learn about the beneficial aspects of not only CBD but CBDa, THC, THCa, THCv, CBN, CBG, CBC as well as the over 200 turpenes which give cannabis its distinctive smell.
The more we learn about this amazing plant the more impressed it becomes. When considering purchasing your next batch of hemp take the time to learn about what is being sold and become an educated consumer.
Posted by the US Hemp Roundtable
US Hemp Roundtable
Last fall, in a bombshell for the hemp industry, the World Health Organization’s Expert Committee on Drug Dependence delivered its preliminary judgment that hemp-derived CBD is safe and well-tolerated in humans (and animals), and is not linked with any negative public health concerns. The World Health Organization also concluded that CBD does not induce physical dependence and is not associated with abuse potential.
In the coming months, the WHO will meet again to issue its final guidance, as it considers whether or not to recommend any international restrictions for hemp-derived CBD and other cannabis products. As part of its formal process, the WHO asked the US Food and Drug Administration for its response, and the FDA has asked for public comment.
The US Hemp Roundtable, the hemp industry’s national business association that represents over thirty firms and organizations across the country – at each link of the hemp supply and sales chain – as well as all of its major national grassroots organizations, submitted its formal comments yesterday. In sum, the Roundtable strongly recommends against the scheduling of hemp-derived CBD as an international controlled substance. The Roundtable argues that CBD derived from hemp is not a controlled substance and has many medicinal and non-medicinal uses. It further urges FDA to include in its evaluation the evidence demonstrating the low abuse and dependence potential, safety, and health benefits of hemp-derived CBD – all of which were recognized by WHO in its recent report on CBD and have been confirmed by the totality of scientific evidence.
Click here to read the Roundtable’s full submission.
For the pharmacology geeks among us…
The metabotropic glutamate 5 receptor and the cannabinoid type 1 receptor are G protein-coupled receptors that are widely expressed in the central nervous system. Metabotropic glutamate 5 receptors, present at the postsynaptic site, are coupled to Gαq/11 proteins and display an excitatory response upon activation, whereas the cannabinoid type 1 receptor, mainly present at presynaptic terminals, is coupled to the Gi/o protein and triggers an inhibitory response. Recent studies suggest that the glutamatergic and endocannabinoid systems exhibit a functional interaction to modulate several neural processes. In this review, we discuss possible mechanisms involved in this crosstalk and its relationship with physiologic and pathologic conditions, including nociception, addiction, and fragile X syndrome.
Stakeholders advocating for cannabidiol (CBD) have crossed a second important hurdle as a preliminary evaluation of the substance by the World Health Organization (WHO) in Vienna last week produced positive findings.
CBD has been under pre-review by WHO as a potential psychotropic substance, with the risk WHO could propose controls similar to those for THC. WHO’s evaluations eventually go to the UN Commission on Narcotic Drugs (CND).
“This round has ended up favorably, but the critical review of CBD will happen in May,” said Boris Baňas (The Hemp Cooperative, Slovakia), board member at the European Industrial Hemp Association (EIHA). The Association joined the Foundation for Alternative Approaches to Addiction (FAAAT) in drafting a joint statement of guidance ahead of the most recent WHO evaluation.
The next review is expected at WHO’s 40th Expert Committee on Drug Dependence (ECDD) meeting in May or June, 2018.
CBD had previously been given a green light at the 39th meeting of the ECDD in Geneva in early November.
EIHA lauded the work of independent WHO experts, who found:
- No case reports of abuse or dependence relating to the use of CBD.
- No public health problems (e.g. impaired driving) should be associated with the use of CBD
- No evidence that CBD as a substance is liable to similar abuse and similar ill-effects as substances in the 1961 or 1971 Conventions (including cannabis and THC).
- CBD is being actively explored for a range of therapeutic applications and has demonstrated effectiveness in treating some forms of epilepsy.
In addition to Baňas, EIHA was represented by associate member Hana Gabrielová, Hempoint, Czech Republic. FAAAT was represented by Kenzi Riboulet Zemouli, Farid Ghehiouèche and Amy Case King. Other CBD proponents present were Michael Krawitz (Veterans for Medical Cannabis Access, USA), Raul Hector Elizalde Garza (Por Grace, Mexico), Dusan Nolimal and Tanja Bagar (International Institute for Cannabinoids, Slovenia) and Marie Nougier (International Drug Policy Consortium).
The following companies supported a campaign backing the EIHA-FAAT effort before WHO: Bluebird Botanicals, Buddingtech, CannaWell, CBD life UK, CBD oils UK, CBDepot.eu, Deep Nature Project, Greenindustries.shop, Hemp and humanity, HempConsult GmbH, Hempflax, Hempire Ltd., Hempoint.cz, Hempura, MCU Botanicals, MeetHarmony, MH medical hemp GmbH.